HealthEquity (HQY) Raises Guidance As Earnings Put Valuation Back In Focus

HealthEquity earnings and guidance put fresh focus on the stock

HealthEquity (HQY) has moved back into focus after its second quarter update on 27 August 2026. The company reported higher revenue and net income compared with a year earlier and raised full year earnings guidance.

Despite the stronger second quarter figures and higher full year guidance on 27 August 2026, HealthEquity’s recent share price performance has cooled, with the stock down 8% over the past month even after an approximately 8% gain over the past quarter. At around $96.07, that softer near term share price return contrasts with a 5% 1 year total shareholder return and a total shareholder return of about 41% over three years. This points to past momentum now easing as the market reassesses growth prospects and risk following the guidance update, ongoing share repurchases and the latest shelf registration filing.

Spot similar earnings and guidance stories by scanning our hand picked 19 high quality undiscovered gems that, like HealthEquity, sit at the intersection of growing fundamentals and shifting market expectations.

After the post earnings pullback, the question for HealthEquity is whether the raised guidance and ongoing buybacks still leave meaningful upside on the table, or whether the stock has already done most of the hard work ahead of a valuation check.

Most Popular Narrative: 16.9% Undervalued

With HealthEquity last closing at $96.07 against a narrative fair value estimate of $115.56, the current setup hinges on how future margins and growth play out under a 7.11% discount rate.

The recent regulatory expansion, allowing direct primary care, pre-deductible telehealth, and millions of new ACA bronze/catastrophic plan members to qualify for HSAs, creates the largest addressable market increase in two decades and is described as poised to accelerate new account openings and AUM growth, which in turn is framed as meaningfully boosting future revenue.

Read the complete narrative.

Curious what kind of revenue path and margin profile this narrative is baking in. The story leans on steadier top line growth and higher earnings per share. This looks at how those building blocks compare with today’s price and that 7.11% discount rate.

Result: Fair Value of $115.56 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the HealthEquity story still hinges on interest income and a healthy labor market, so weaker hiring or lower rates could quickly challenge these margin assumptions.

Find out about the key risks to this HealthEquity narrative.

Another view on HealthEquity valuation

The narrative model points to HealthEquity trading below a fair value estimate. The picture looks different when using P/E. The stock trades on 33.6x compared with a fair ratio of 26.7x, the US Healthcare industry at 25.3x and direct peers at 37.5x. That mix hints at richer pricing than the fair ratio suggests, so it is worth considering how much weight to give to the growth story reflected in today’s multiple.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mixed messages on HealthEquity might leave you unsure what to make of the setup. Consider taking a closer look while sentiment is still forming and weigh the 4 key rewards

Looking for more investment ideas beyond HealthEquity?

If HealthEquity has your attention, do not stop there. The wider market still offers plenty of opportunities that could fit your style and risk comfort.

• Target potential mispricings by scanning a focused set of 47 high quality undervalued stocks that pair solid fundamentals with more modest expectations.
• Strengthen the income side of your portfolio by reviewing 11 dividend fortresses that combine higher yields with an emphasis on resilience.
• Prioritise resilience first and search through 82 resilient stocks with low risk scores that score well on financial stability and volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com